enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $33.67.

Several research analysts recently commented on ENGN shares. Oppenheimer started coverage on enGene in a research note on Wednesday, August 28th. They issued an “outperform” rating and a $30.00 price target on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th.

enGene Price Performance

Shares of NASDAQ ENGN opened at $7.21 on Friday. enGene has a 1-year low of $4.94 and a 1-year high of $43.00. The business has a 50-day moving average of $7.30 and a 200-day moving average of $11.13. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 42.80. The company has a market capitalization of $318.44 million, a price-to-earnings ratio of -4.34 and a beta of -0.67.

enGene (NASDAQ:ENGN) last issued its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, equities analysts anticipate that enGene will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Altitude Crest Partners Inc. bought a new position in enGene during the 1st quarter valued at $2,039,000. SR One Capital Management LP bought a new position in enGene during the 2nd quarter valued at $4,715,000. Omega Fund Management LLC bought a new position in enGene during the 4th quarter valued at $10,441,000. Logos Global Management LP boosted its stake in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in enGene during the 1st quarter valued at $17,095,000. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.